A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

You may be eligible if

• Have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis and be a candidate for treatment with Raptiva
• Are being treated with or initiating Raptiva therapy at the time of enrollment
• Be able to provide written informed consent
• Be willing and able to fully to participate for the duration of patient follow-up (5 years)
• Exclusion Criterion:
• Have previously received at least one dose of Raptiva and are not currently using or restarting treatment with Raptiva at the time of enrollment